Searchable abstracts of presentations at key conferences in endocrinology

ea0029oc2.5 | Thyroid Clinical I | ICEECE2012

Thyroid spongiform nodules are the best candidates for percutaneous laser ablation. A 5 year follow-up study in 72 patients

Valcavi R. , Bortolani G. Stecconi , Riganti F. , Pacella C.

Background: Percutaneous laser ablation (LA) is a therapeutic procedure used for the reduction of benign thyroid nodules. After LA a 50% nodule reduction was observed by most authors. However, eligibility criteria for LA based on long term efficacy have not been established.Methods: Seventy-two patients (51 women and 21 men) with benign cold thyroid solitary nodules or a dominant nodule within a normo-functioning multinodular goiter underwent thermal Nd:...

ea0041ep1094 | Thyroid cancer | ECE2016

Thyroid nodule ultrasound: which indication for FNA? a prospective study

Riganti Fabrizio , Bonelli Nadia , Rossetto Ruth , Pacchioni Donatella , Viberti Laura , Maccario Mauro , Ghigo Ezio , Garberoglio Roberto

Introduction: Thyroid nodules are discovered by ultrasound (US) in a large percentage of population. In most cases they are benign and asymptomatic. When to perform or not a fine-needle-aspiration (FNA) is still matter of debate. Aim of this study was to evaluate the usefulness of a easy-to-use US classification, based on three US classes.Methods: We prospectively evaluated US features of 1118 thyroid nodules, allocating each nodule in one of three class...

ea0022oc2.6 | Thyroid | ECE2010

Percutaneous laser ablation (PLA) in non-functioning benign thyroid nodules: a 3-year follow-up study

Valcavi Roberto , Riganti Fabrizio , Bertani Angelo , Formisano Debora , Pacella Claudio M

Aim of the study: To evaluate efficacy and safety of ultrasound-guided percutaneous laser ablation (PLA) on benign thyroid nodule size reduction, thyroid function and autoimmunity.Methodology: This study was approved by local institutional review committee. All data are mean±S.D. Two hundred and ninety-eight euthyroid outpatients (F=241, M=57; age 50.7±12.0 years) with a benign thyroid nodule (volume 23.1±21.3 ml) causing ei...

ea0014p575 | (1) | ECE2007

The GH releasing activity of ghrelin is insensitive to the negative growth hormone (GH) autofeedback in humans

Riganti Fabrizio , Prodam Flavia , Gramaglia Elena , Benso Andrea , Lucatello Barbara , Ghigo Ezio , Broglio Fabio

Growth hormone (GH) secretion is regulated by a complex interplay between GH-releasing hormone (GHRH), somatostatin and several other central and peripheral modulatory signals. Ghrelin has been hypothesized as physiological amplifier of GH pulsatility and acts via mechanisms, at least partially, independent of GHRH and somatostatin. The GH response to GHRH is strongly inhibited by previous administration of recombinant human GH (rhGH), likely as a consequence of a somatostatin...

ea0011p897 | Thyroid | ECE2006

The GH response to ghrelin in humans is reduced in conditions of hyper- and hypothyroidism

Broglio F , Prodam F , Riganti F , Gramaglia E , Rossetto R , Maccario M , Ghigo E

Both hyper- and hypothyroidism show reduced spontaneous and GHRH-stimulated GH secretion. Although impaired GHRH secretion and activity as well as reduced GH pituitary synthesis have been reported in these pathological conditions, a definitive description of the underlying pathophysiological mechanisms have not been provided yet. Ghrelin elicits a potent GH-releasing effect partially mediated by a functional somatostatin antagonism and a synergic interaction with GHRH. Moreove...

ea0011p925 | Thyroid | ECE2006

Thyrotoxicosis is coupled with quantitative and qualitative sleep disruptions

Riganti F , Prodam F , Gramaglia E , van Cauter E , Ghigo E , Broglio F

Despite the common clinical opinion that thyrotoxicosis is associated with quantitative and qualitative sleep alterations, at present, an objective evaluation of sleep quality and quantity in this clinical condition has never been performed so far. Based on this foregoing, in order to perform a qualitative and quantitative description of sleep in this clinical condition, we enrolled 6 normal-weighted patients suffering from naïve overt hyperthyroidism due to Basedow Disea...

ea0020oc4.5 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Regulation of obestatin levels during unacylated ghrelin infusions in normal and type 2 diabetic patients

St-Pierre David H , Settanni Fabio , Olivetti Ilaria , Gramaglia Elena , Benso Andrea , Riganti Fabrizio , Ghigo Ezio , Broglio Fabio

Background: Obestatin, a ghrelin gene product was recently isolated but important questions remain regarding its regulation and its physiological effects. The aim of the present study was to evaluate the effect of unacylated ghrelin (UAG) on obestatin levels in normal subjects and patients with type 2 diabetes (T2D).Methods: Five normal subjects and 5 T2D patients were included in this study. Unacylated ghrelin (3 μg/kg per hour) or saline were cont...

ea0020p117 | Thyroid | ECE2009

Subjective and objective sleep evaluation in patients with hypo- and hyper-thyroidism

Riganti Fabrizio , Noi Fabiana Di , Seardo Maria Angela , Gramaglia Elena , Bonelli Nadia , Rossetto Ruth , Ghigo Ezio , Broglio Fabio

Hyper- and hypo-thyroidism are considered as clinical conditions of sleep alterations. At present, however, these clinical reports have never been confirmed by studies providing a structured description of subjective and objective sleep quantity and quality. To this aim, we enrolled 15 patients with naïve overt hyperthyroidism (HYPER), 9 with naïve overt primary hypothyroidism (HYPO) and 15 healthy age-, sex- and BMI-matched control subjects (CS). Clinical conditions...

ea0020p439 | Obesity and Metabolism | ECE2009

The evaluation of metabolic effects following ghrelin and salbutamol administration

Benso Andrea , St-Pierre David H , Gramaglia Elena , Riganti Fabrizio , Lucatello Barbara , Olivetti Ilaria , Ghigo Ezio , Broglio Fabio

Background: The activation of the GHS-R1a receptor by acylated ghrelin (AG) or by synthetic GH secretagogues (GHS), potently stimulates GH release and mediates other neuroendocrine/metabolic effects. Beta-adrenergic receptor agonists negatively influence GH secretion and other metabolic functions. The GH response to AG and GHS is refractory to the inhibitory effect of β2-adrenoceptors activation but no other report has evaluated the interactions between AG and salbutamol ...

ea0016p532 | Obesity | ECE2008

Diabetogenic effects of a continuous infusion of acylated ghrelin in normal and type 2 diabetic patients

St-Pierre David H , Olivetti Ilaria , Pomero Elisa , Gramaglia Elena , Riganti Fabrizio , Benso Andrea , Ghigo Ezio , Broglio Fabio

Background: Previous studies have shown that acylated ghrelin (AG) modulates insulin secretion and glucose disposal in vitro and after acute administration in humans. The aim of the present study was to evaluate postprandial glucose and insulin response following AG infusion in normal subjects and patients with type 2 diabetes.Methods: Six normal subjects and 3 patients with type 2 diabetes were included in this study. AG (1 μg/kg per h) or s...